奥氮平在预防晚期非小细胞肺癌患者化疗所致恶心、呕吐中的临床应用

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (0 KB) HTML (39 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect and safety of Olanzapine in preventing nausea and vomiting caused by chemotherapy in patients with advanced non-small cell lung cancer.Methods A total of 50 patients with advanced non-small cell lung cancer chemotherapy-induced nausea and vomiting in Dalian Friendship Hospital from November 2016 to November 2019 were selected, and they were divided into the observation group (n=25) and the control group (n=25) by the random number table method.Both groups were given Cisplatin combined with Paclitaxel/Docetaxel chemotherapy.Patients in the control group were treated with Ondansetron Hydrochloride Injection preventively,and in the observation group, they were treated with Olanzapine combined with Ondansetron Hydrochloride Injection to stop vomiting.The complete remission rate of nausea and vomiting after chemotherapy was recorded.The quality of life and incidence of adverse reactions between the two groups were compared.Results There was no significant difference in the complete remission rate of acute nausea and acute vomiting between the two groups (P＞0.05).The complete remission rates of delayed nausea and delayed vomiting in the observation group were higher than those in the control group, and the differences were statistically significant (P＜0.05).The emotional function score on the quality of life scale of the observation group was higher than that of the control group, and the difference was statistically significant(P＜0.05).The nausea, vomiting and decreased appetite scores on the quality of life scale of the observation group were lower than those of the control group, and the differences were statistically significant (P＜0.05).The incidence of drowsiness and dizziness in the observation group was higher than that in the control group, and the difference was statistically significant (P＜0.05).Conclusion Olanzapine has a good effect on preventing delayed nausea and vomiting caused by chemotherapy in patients with advanced nonsmall cell lung cancer, and it can improve the quality of life of patients.

Key words： Olanzapine Nausea Vomiting Quality of life

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Lei
	WANG Ming-ji

Cite this article:

WANG Lei,WANG Ming-ji. Clinical application of Olanzapine in preventing nausea and vomiting caused by chemotherapy in patients with advanced non-small cell lung cancer[J]. 中国当代医药, 2021, 28(8): 84-88.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I8/84

[1]	Siegel RL，Miller KD，Jemal A.Cancer statistics，2018[J].CA Cancer J Clin，2018，68（1）：7-30.
[4]	姜文奇，巴一，冯继锋，等.肿瘤药物治疗相关恶心呕吐防治中国专家共识（2019年版）[J].中国医学前沿杂志（电子版），2019，11（11）：16-26.
[2]	Lima ABC，Macedo LT，Sasse AD，et al.Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer：a systematic review and meta-analysis[J].PLoS One，2011，6（8）：e22681.
[3]	Hori K，Kobayashi N，Atsumi H，et al.Changes in compliance with Japanese antiemetic guideline for chemotherapyinduced nausea and vomiting：a nationwide survey using a distributed research network[J].Support Care Cancer，2014，22（4）：969-977.
[5]	Cabaleiro T，Lopez-Rodriguez R，Ochoa D，et al.Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects[J].Hum Psychopharmacol，2013，28（3）：205-214.
[6]	Rami-Porta R，Bolejack V，Crowley J，et al.Proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer[J].J Thorac Oncol，2015，10（7）：990-1003.
[7]	Wan C，Meng Q，Yang Z，et al.Validation of the simplified Chinese version of EORTC QLQ-C30 from the measurements of five types of in patients with cancer[J].Ann Oncol，2008，19（12）：2053-2060.
[8]	Ayana BA，Negash S，Yusuf L，et al.Reliability and Validity of Amharic Version of EORTC QLQ-C 30 Questionnaire among Gynecological Cancer Patients in Ethiopia[J].PLoS One，11（6）：e0157359.
[9]	Nakashima K，Murakami H，Yokoyama K，et al.A phase Ⅱstudy of palonosetron，aprepitant，dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapyinduced nausea and vomiting in patients with thoracic malignancy[J].Jpn J Clin Oncol，2017，47（9）：840-843.
[10]	Richardson JL，Marks G，Levine A.The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy[J].J Clin Oncol，1988，6（11）：1746-1752.
[11]	Craig JB，Powell BL.The management of nausea and vomiting in clinical oncology[J].Am J Med Sci，1987，293（1）：34-44.
[12]	Borison HL，Wang SC.Physiology and pharmacology of vomiting[J].Pharmacol Rev，1953，5（2）：193-230.
[13]	Seigel LJ，Longo DL.The control of chemotherapy-induced emesis[J].Ann Intern Med，1981，95（3）：352-359.
[14]	刘雷，丁琛琛，王俊，等.小剂量奥氮平改善女性肺癌患者高致吐性化疗导致的延迟性恶心和呕吐[J].肿瘤学杂志，2017，23（3）：251-253.
[15]	Yang T，Liu QX，Lu M，et al.Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting：a meta-analysis[J].Br J Clin Pharmacol，2017，83（7）：1369-1379.
[16]	Sutherland A，Naessens K，Plugge E，et al.Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults[J].Cochrane Database Syst Rev，2018，9（9）：CD012555.
[17]	Osman AAM，Elhassan MMA，AbdElrahim BHA，et al.Olanzapine for the prevention of chemotherapy-induced nausea and vomiting：A comparative study from Sudan[J].J Glob Oncol，2018，4：1-9.
[18]	Shivaprakash G，Karthik S，Sarayu V，et al.Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin cyclophosphamide regimen：A prospective，nonrandomized，open-label study[J].Indian J Pharmacol，2017，49（6）：451-457.
[19]	Tan LJ，Liu JT，Liu XL，et al.Clinical research of Olanzapine for the prevention of chemotherapy-induced nausea and vomiting[J].J Exp Clin Cancer Res，2009，28（1）：131-137.
[20]	吴锡林，王均惠，陈建新.奥氮平预防非小细胞肺癌化疗顺铂方案所致恶心呕吐[J].肿瘤学杂志，2019，25（3）：264-267.
[21]	何慧丽，袁东东.乳腺癌联合治疗方案中辅助化疗所致恶心呕吐应用奥氮平的临床疗效分析[J].中国医学工程，2019，27（10）：110-112.
[22]	何尚香，欧丹贞.奥氮平三联止吐方案对中度致吐化疗患者临床疗效观察[J].深圳中西医结合杂志，2019，29（21）：137-138.